Research map: Peripheral blood CD19+B cell proportion at baseline predicts early complete response to belimumab treatment in patients with refractory lupus nephritis

Back to the article

Papers in this map

  1. 2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis · Lisa R. Sammaritano · 2025 · 119 citations · Cited by this paper
  2. Old marker, new face: anti-RNP as a sentinel of coronary and peripheral endothelial dysfunction in systemic lupus erythematosus · 2026 · Related
  3. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus · Van Trung Chu · 2009 · 114 citations · Cited by this paper
  4. Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus · 2026 · Related
  5. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update · Antonis Fanouriakis · 2025 · 97 citations · Cited by this paper
  6. Twelve-month follow-up after telitacicept withdrawal in patients with SLE: a single-centre study · 2026 · Related
  7. B cell-targeted therapies in systemic lupus erythematosus · Leah Arbitman · 2022 · 73 citations · Cited by this paper
  8. Reference intervals for aCL and anti-β2GPI IgAGM antibodies in a large health-inspection population: a foundational study for combined-isotype assay interpretation · 2026 · Related
  9. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population · Xueqing Yu · 2022 · 51 citations · Cited by this paper
  10. Clinical value of simultaneous detection of anti-dsDNA and anti-chromatin antibodies using a multiplex immunoassay in systemic lupus erythematosus: a 5-year retrospective study · 2026 · Related
  11. Lupus nephritis: redefining the treatment goals · An S. De Vriese · 2024 · 51 citations · Cited by this paper
  12. Left Ventricular Mass Index as an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with SLE · 2026 · Related
  13. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort · Mariele Gatto · 2021 · 45 citations · Cited by this paper
  14. Risk of falls, recurrent falls and osteoporotic fractures in SLE patients with comorbid fibromyalgia: a propensity score-matched cohort study using the TriNetX Network · 2026 · Related
  15. Expert Perspective: An Approach to Refractory Lupus Nephritis · Swati Arora · 2022 · 36 citations · Cited by this paper
  16. Belimumab induces early and sustained resolution of lupus thrombocytopenia · 2026 · Related
  17. Predictors of renal flares and long-term renal outcome in patients with lupus nephritis: results from daily clinical practice · G. Ligtenberg · 2022 · 23 citations · Cited by this paper
  18. Clinical utility and performance of anti-C1q antibodies for SLE: comparative analysis of three different assays · 2026 · Related
  19. Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study · Yi‐Ting Chen · 2025 · 15 citations · Cited by this paper
  20. Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis · 2026 · Related
  21. Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study · Hui-Zhi Jin · 2024 · 14 citations · Cited by this paper
  22. Targeted therapies for lupus nephritis: Current perspectives and future directions · Xiuzhi Jia · 2023 · 10 citations · Cited by this paper
  23. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study · Shuoyang Zhang · 2023 · 9 citations · Cited by this paper
  24. Efficacy, safety and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry · Hidenori Sakai · 2024 · 8 citations · Cited by this paper
  25. Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis · Liling Zhao · 2024 · 6 citations · Cited by this paper
  26. Efficacy and safety of belimumab in refractory and newly diagnosed active lupus nephritis patients: a real-world observational study · Ying Ma · 2025 · 6 citations · Cited by this paper
  27. Biological targeted therapy for lupus nephritis–the role of BLYS and APRIL · Xin Yang · 2025 · 4 citations · Cited by this paper
  28. Refractory lupus nephritis: current Understanding and emerging treatment strategies · Tingting Ding · 2025 · 3 citations · Cited by this paper
  29. Predictors of long-term renal survival and mortality in patients with proliferative and membranous lupus nephritis · Jung-Min Shin · 2026 · 3 citations · Cited by this paper
  30. Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis · Brad H. Rovin · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)